JGC
VRDN icon

J. Goldman & Co’s Viridian Therapeutics VRDN Stock Holding History

J. Goldman & Co’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,000
Closed -$153K – 656
2024
Q4 		$153K Buy
+8,000
New +$174K ﹤0.01% 410

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

J. Goldman & Co's VRDN Position: Q2 2026 in Review

J. Goldman & Co sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 15,598 shares — an estimated $251K sold.

J. Goldman & Co first reported a position in VRDN in Q1 2024 and held it in 8 quarters. The position peaked at $3.44M in Q4 2024. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • J. Goldman & Co reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • J. Goldman & Co sold 15,598 Viridian Therapeutics shares in Q2 2026, an estimated $251K.
  • J. Goldman & Co first reported a position in Viridian Therapeutics in Q1 2024 and held it in 8 quarters.
  • J. Goldman & Co's Viridian Therapeutics position peaked at $3.44M in Q4 2024.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.